和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO STRATEGIC COLLABORATION WITH SINOPHARM

This announcement is made by HBM Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has entered into a strategic collaboration agreement with China National Pharmaceutical Group Co., Ltd. ("**Sinopharm**") to establish the Sinopharm – Harbour BioMed Innovation Consortium (the "**Innovation Consortium**") and collaborate on the research and development of innovative biologics, with a strategic focus on oncology, immune-mediated inflammatory diseases and other therapeutic areas (the "**Strategic Collaboration**").

Under the Strategic Collaboration, the Group and Sinopharm will collaborate across the full research and development lifecycle of innovative biologics, with a strategic focus on oncology, immune-mediated inflammatory diseases and other therapeutic areas. The Group will leverage its globally leading Harbour Mice® fully human antibody technology platform and AI-enabled drug discovery capabilities to drive the discovery and optimization of antibody candidates with Sinopharm, including but not limited to target validation, lead antibody discovery and optimization, antibody format design, and antibody engineering. Sinopharm will contribute their expertise in clinical development, large-scale manufacturing and commercialization, and will develop commercial-scale manufacturing processes, producing clinical trial materials, and commercializing products arising from the collaboration. The two parties will jointly fund the research and development activities and share product rights in accordance with mutually agreed terms.

Cautionary Statement: We cannot guarantee that any drug candidate will be successfully developed or ultimately marketed by the Company and/or its collaboration partners. Shareholders and potential investors of the Company are advised to exercise due care when dealing with the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 27 July 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.